We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

14 hedge funds and large institutions have $3.88M invested in Decoy Therapeutics in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

516% more capital invested

Capital invested by funds: $630K → $3.88M (+$3.25M)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

40% more funds holding

Funds holding: 10 → 14 (+4)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
+$1.35M
2
Squarepoint
Squarepoint
New York
+$87.9K
3
WVP
Worth Venture Partners
New Jersey
+$87.9K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$58.6K
5
XSC
X-Square Capital
Puerto Rico
+$58.6K

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$29.3K
2
TRCT
Tower Research Capital (TRC)
New York
-$29.3K
3
Two Sigma Investments
Two Sigma Investments
New York
-$10K

DCOY Hedge Fund Activity: Q4 2020 in Review

14 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2020, worth a combined $3.88M — up 516% from $630K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new DCOY positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.35M. The largest seller was Northern Trust, exiting entirely with an estimated $29.3K sold.

  • 14 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2020, up from 10 in Q3 2020.
  • Funds reported $3.88M of Decoy Therapeutics stock for Q4 2020, up 516% quarter-over-quarter.
  • 6 funds opened new Decoy Therapeutics positions in Q4 2020 and 2 closed out, a net change of +4 holders.
  • The largest Decoy Therapeutics buyer in Q4 2020 was Sio Capital Management, an estimated $1.35M added.
  • The largest Decoy Therapeutics seller in Q4 2020 was Northern Trust, an estimated $29.3K sold.

Based on aggregated 13F filings for Q4 2020.